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ChimeraWe generated a replicating chimeric measles virus in which the hemagglutinin and fusion surface
glycoproteins were replaced with the gp160 envelope glycoprotein of simian immunodeﬁciency virus
(SIVmac239). Based on a previously cloned live-attenuated Schwarz vaccine strain of measles virus (MV), this
chimera was rescued at high titers using reverse genetics in CD4+ target cells. Cytopathic effect consisted
in the presence of large cell aggregates evolving to form syncytia, as observed during SIV infection. The
morphology of the chimeric virus was identical to that of the parent MV particles. The presence of SIV gp160
as the only envelope protein on chimeric particles surface altered the cell tropism of the new virus from
CD46+ to CD4+ cells. Used as an HIV candidate vaccine, this MV/SIVenv chimeric virus would mimic
transient HIV-like infection, beneﬁting both from HIV-like tropism and the capacity of MV to replicate in
dendritic cells, macrophages and lymphocytes.l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Almost thirty years after human immunodeﬁciency virus (HIV)
was identiﬁed as the causative agent of AIDS, a vaccine capable of
preventing the infection remains elusive. In 2003, the ﬁrst phase III
efﬁcacy trial of an HIV candidate vaccine demonstrated that a
monomeric recombinant gp120 (AIDSVax) was unable to elicit
detectable neutralizing antibodies or to reduce viral load (Flynn et
al., 2005; Pitisuttithum et al., 2006). In 2008, the STEP phase IIb trial of
an Ad5-based vaccine challenged the rationale underlying T-cell-
based vaccine strategies, as speciﬁc T cell responses induced by the
vaccine also failed to prevent HIV infection or to reduce viral load
(Buchbinder et al., 2008; McElrath et al., 2008). Recently, the RV144
phase III trial conducted in Thailand showed that a prime-boost
strategy combining 6 doses of live-recombinant ALVAC-HIV with 2
doses of gp120 B/E envelope in at-risk healthy volunteers reduced the
incidence of infection by 31% (Rerks-Ngarm et al., 2009). This very
encouraging result demonstrated that both T cells and antibodies are
required to prevent HIV infection, and that a prime-boost strategy is
necessary to induce both arms of the immune system. However, the
complex dosing schedule and weak protection provided by this
strategy makes it impractical.An ideal vaccine would induce effective and long-lasting responses
after one or two administrations and be amenable to low-cost mass
production. To address these challenges, we have previously
developed a vector derived from the pediatric live-attenuated
Schwarz vaccine strain of measles virus (MV) (Combredet et al.,
2003). Different HIV and SIV proteins were stably expressed from MV
vectors and strong and durable speciﬁc humoral and cellular immune
responses were induced in mice (Guerbois et al., 2009; Liniger et al.,
2009; Lorin et al., 2004, 2005a; Wang et al., 2001). MV vaccine is a
live-attenuated negative-stranded RNA virus proven to be one of the
safest and most effective human vaccine products. Mass-produced in
many countries and distributed at low cost through the Extended
Program on Immunization, the MV vaccine induces life-long immu-
nity after one or two injections. We subsequently initiated clinical
development of an HIV candidate vaccine based on a recombinant MV
encoding an HIV Gag-Pol-Nef antigen. This ﬁrst-generation MV–HIV
vector was designed to induce cellular immunity in adults with
preexisting immunity to measles, to evaluate for the ﬁrst time a
replicating vector as an HIV vaccine, and to prepare the GMP and
regulatory logistics for such a vaccine. A phase I clinical trial of this
candidate vaccine was recently launched.
Measles vaccine provides very effective protection from an
infection acquired through the respiratory mucosa. The effectors are
both long-lived B cells that produce neutralizing antibodies to the
viral glycoproteins, and long-lived CD4 and CD8 T cells. These
effectors are rapidly mobilized in the respiratory mucosa on natural
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of MV infection in the macaque model has shown that the ﬁrst cells
infected are mucosal dendritic cells (de Swart, 2008; Lemon et al.,
2011). Mucosal tissues are also the main portals of entry for HIV-1.
After transmission, HIV-1 crosses the mucosal barrier in a few hours
and disseminates locally to draining lymph nodes after a few days
(Pope and Haase, 2003). Systemic dissemination then occurs, with a
high rate of virus replication in blood cells during the following
month. Thus, to induce sterilizing immunity to HIV-1, a vaccine must
induce both neutralizing antibodies and cytolytic T lymphocytes
(CTLs) at mucosal surfaces (Letvin, 2006). These effectors must either
be present at the time of natural exposure or be raised within a few
hours or days.
Here, to exploit the ability of the live-attenuated MV to induce
potent mucosal immunity to its surface glycoproteins, we developed a
new approach based on an MV–HIV chimera rather than a
recombinant MV vector. The chimeric virus was obtained by replacing
the MV fusion (F) and hemagglutinin (H) glycoprotein genes by the
HIV gp160 coding sequence expressed as an MV transcript in a
recombinant MV vector. The resulting virus expresses native HIV
gp160 spikes on its surface, instead of MV H/F glycoproteins. It should
therefore have the twin advantages of HIV tropism andMV replication
in dendritic cells, macrophages and lymphocytes, thus mimicking
transient HIV infection. It should also exhibit the genetic stability and
safety features of MV vaccine strains that include no recombination
with other segmented negative-stranded RNA viruses, a cytoplasmic
replicative cycle, no host genome integration, no persistence, and no
shedding. Moreover, this chimera should be cleared from the host by
the immune reaction it induces.
With the aim of evaluating its vaccine efﬁcacy in the macaque
model, we ﬁrst generated aMV–SIV chimera based on SIVmac239, one
of the most widely used model for AIDS in macaques. We constructed
the chimera by deleting the fusion (F) and hemagglutinin (H)
glycoprotein genes from MV Schwarz vaccine strain antigenomic
cDNA and replacing themby the SIVMac239 gp160 sequence as anMV
transcript. The chimeric virus was rescued with a reverse genetics
system and produced at high titers in CEMx174 cells. SIV gp160 was
efﬁciently expressed on the surface of infected cells and on viralFig. 1. Construction of MV-SIVenv-RFP chimeric virus. Schematic representation and genomi
(C) The fusion (F) and hemagglutinin (H) glycoproteins of the MVSchw vaccine strain were
Intracytoplasmic tail of the fusion protein (FIC) was conserved and placed in fusion with the gparticles. The new virus exhibited typical CD4 tropism and induced
syncytia formation by CD4 T cells.
Results
Generation of chimeric MV expressing SIVMac239 gp160 instead of the
MV H/F envelope glycoproteins
To improve the capacity of our previous pTM-MVSchw vector to
elicit broad-spectrum neutralizing antibodies to HIV by expressing
native trimeric gp160 on the viral surface, we designed a new MV
chimeric vector in which the MV fusion (F) and hemagglutinin (H)
envelope glycoproteins genes were deleted and replaced by the gp160
sequence expressed from an MV transcript. As proof-of-concept, and
with the aim of evaluating vaccine efﬁcacy in the macaque model, we
generated an MV–SIV chimeric virus based on SIVmac239 gp160
(Fig. 1). To promote efﬁcient expression of SIV gp160 glycoprotein at
the surface of chimeric viral particles, we replaced the intracytoplas-
mic domain of gp160 with that of the MV fusion protein, thus
permitting cell membrane anchoring through interactions with the
MV matrix protein, as previously demonstrated (Foley et al., 2002;
Spielhofer et al., 1998). To visualize the chimeric virus in infected cells,
we inserted the RFP Cherry protein sequence as an additional
transcription unit, upstream of the MV-M matrix protein. This
additional transcription unit may be used in future to insert other
genes in place of RFP.
To construct the chimeric cDNA, the genomic region encompassing
theMV fusion (F) and hemagglutinin (H) genes (NarI to SpeI fragment
in Fig. 1A) was deleted from the vector plasmid pTM-MV-Schw and
replaced by a synthetic chimeric MV–SIV sequence (Fig. 1B). This
chimeric sequence (Fig. 1C) was designed to preserve the complete
promoter and intergenic sequence of the MV-F gene upstream of the
SIV gp160 initiation codon, such that the gp160 gene is expressed as
an MV transcript. The whole gp120 and the gp41 ectodomain with its
transmembrane sequence deleted of the intracytoplasmic domain
were fused to the MV-F intracytoplasmic sequence, followed by the
MV H/L intergenic region. This synthetic sequence was then
introduced into the pTM-MVSchw-RFP-STREPtag plasmid, and thec organization of MV (A) and chimeric MV-SIVenv (B) (N, P, M, F, H, L are MV proteins).
replaced by the extracellular and transmembrane (TM) part of the gp160 of SIVmac239.
p41 in order to anchor the glycoprotein with the Mmatrix protein of the measles virus.
Fig. 2. Rescue and culture of MV/SIVenv-RFP chimeric virus. (A) To rescue the chimeric
virus, the plasmid pTM-MVSchw-Chim-SIVenv (Cherry) was transfected in HEK-293T
helper cells that were subsequently co-cultured with MT4 or CEMx174 cells. After 3 to
5 days of co-culture, cytopathic effect occurred showing syncytia bubbling from cell
aggregates and expressing the cherry protein. (B) CEMx174 cells were infected by cell-
free MV/SIVenv chimeric virus at MOI=0.1. Typical cell aggregates and bubbling
syncytia were observed at 3 days post-infection.
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was fully sequenced and shown to respect the ‘rule of 6’ of the MV
genome (Calain and Roux, 1993).
MV rescue from cDNA is usually achieved by coculturing
transfected helper cells with MV target cells that express at least
one of the MV receptors (SLAM or CD46) (Vero, MRC5, CEF, B95a)
(Dorig et al., 1993; Naniche et al., 1993; Tatsuo et al., 2000). Given
the expected tropism change of the MV/SIV chimeric virus, we
rescued it from the pTM-MVSchw-Chim-SIVenv (Cherry) plasmid by
using the standard protocol, except that helper cells were cocultured
with SIV CD4+ target cells (MT4, CEMx174). Rescue of the chimeric
virus was only successful when this modiﬁed protocol was used.
Monitoring was facilitated by the presence of ﬂuorescent cells after
3 to 5 days of co-culture (Fig. 2A). A cytopathic effect (CPE) on
CEMx174 cells appeared soon after ﬂuorescence was ﬁrst detected.
The new chimeric virus harvested from infected cells was designat-
ed MV/SIVenv. Other cells, such as MT4 and HeLa P4C5 cells, were
also successfully used to rescue the MV/SIVenv chimeric virus, with
a comparable time course.
Once rescued, the chimeric virus can be ampliﬁed for weeks on
CEMx174 or MT4 cells, simply by adding fresh uninfected cells to
the culture and replacing the medium, as for lentivirus ampliﬁca-
tion. Using the same procedure as for measles virus puriﬁcation,
cell-free virus was collected by freezing and thawing infected cells
with medium then clariﬁcation. New infection of other cells was
carried out with clariﬁed cell-free virus. T cells infected by the MV/
SIVenv chimeric virus exhibited characteristic features of lentiviral
infection with large aggregates of infected cells evolving to form
syncytia (Fig. 2B). Although the MVSchw strain is able to grow at
low titers on CD4 T cells through the use of the SLAM receptor
(Dhiman et al., 2004; Yanagi et al., 2006), the chimeric MV/SIVenv
virus produced 3 log higher titers than control MVSchw on
CEMx174 cells (Fig. 3A). When comparing the rate of replication
of SIV to the MV/SIVenv chimeric virus by FACS analysis (Fig. 3B),
we observed that the chimeric virus replicated faster with the
maximum virus yield achieved at 2–3 days post-infection, while as
expected, SIVmac251 replicated more slowly and required 8–
10 days to achieve 100% of infection. Replication kinetic analysisshowed that the MV/SIVenv chimeric virus achieved titers of up to
106 TCID50/ml within 48–60 h (Fig. 3C), at a similar rate than MV
itself on Vero cells (Fig. 3D). Beyond 60 h the virus titer fell and
most of the cells die after few days. If additional fresh cells are
added, the infection can last several weeks. To determine the best
cell line for virus stock production and titration, we compared the
viral titers obtained with CEMx174 and MT4 cells. CEMx174 cells
reproducibly produced 1 log higher virus titers than MT4 cells.
CEMx174 cells are B-T hybrid lymphoblastic cells (Salter et al.,
1985), a characteristic that might promote MV/SIVenv chimeric
virus replication. The virus might also beneﬁt from both the T cell
entry receptor used by SIVenv glycoproteins and from the efﬁcient
replication of MV in B lymphocytes (Kobune et al., 1990).
The MV/SIVenv chimeric virus expresses SIV gp160
To assess the expression of SIV gp160 glycoprotein by the
chimeric virus, CEMx174 cells were infected with MV/SIVenv and
lysed after 48 h. Cell extracts were separated by SDS-PAGE
electrophoresis and analyzed by Western blotting (Fig. 4). Lysates
of uninfected CEMx174 cells, Vero cells infected by the parental
MVSchw virus expressing the Cherry protein, and CEMx174 cells
infected by SIV Mac239 were used as controls. Both the parental
MVSchw and chimeric MV/SIVenv viruses expressed the MV
nucleoprotein N in infected cells. The SIV gp160 and its mature
gp120 form were detected with the expected molecular size in
cells infected with MV/SIVenv chimeric virus, demonstrating that
the MV-F promoter controls efﬁciently the expression of SIV
glycoproteins. MV/SIVenv chimeric virus expressed a lower level
of SIV glycoproteins than SIVmac251. However, this level is
compatible with the efﬁcient budding and spreading capacity of
the chimeric virus, as shown in Figs. 2B and 3C.
Expression of the SIV gp160 and MV-N proteins was also
demonstrated by immunoﬂuorescence analysis with speciﬁc mono-
clonal antibodies (Fig. 5). Both MV-N and SIV gp160 were expressed
in infected cells, simultaneously with RFP cherry protein. SIV gp160
was expressed on the surface of infected cells, as demonstrated by
positive surface staining of non-permeabilized cells. Large syncytia,
similar to those observed with HeLa cells infected by standard
MVSchw, were particularly prominent with HeLA P4C5 cells that
express the CD4, CXCR4 and CCR5 receptors on their surface. This
demonstrates that SIV gp160 expression by the chimeric virus in
adherent ﬁbroblastic-like cells expressing SIV receptors mediatesMV-
like fusion.
The morphology of MV/SIVenv chimeric particles is similar to that of MV
particles
To determine whether MV-F and H glycoprotein replacement by
SIV gp160 alters the morphological structure of chimeric particles
compared to parental MV, we examined infected cells by transmission
electron microscopy. Hela P4C5 cells were infected with MV-Schw or
MV/SIVenv, then ﬁxed and stained with uranyl acetate and Reynolds
lead citrate 22 h later, before electron microscopy (Fig. 6). In both
cases we observed numerous viral particles either budding or trapped
in the extracytoplasmic space between infected cells, with a structure
and size (150–350 nm) typical of measles virus. Moreover, a fringe of
short spikes was observed on the surface of both MV and chimeric
particles (Figs. 6C and D), corresponding to the MV and SIV
glycoproteins, respectively. These observations showed that MV F
and H replacement by SIV gp160 did not affect the morphology or size
of the resulting viral particles.
Immunoelectron microscopy was used to demonstrate the
presence of SIV gp160 anchored on the surface of the virusmembrane.
Infected cells were immunostained with a speciﬁc anti-SIV gp160/120
antibody before electron microscopy (Fig. 6E). The chimeric viral
Fig. 3. Replication kinetics of MV/SIVenv chimeric virus in CEMX174 T-cells. (A) CEMX174 cells were infected at MOI=0.1 by MVSchw or MV/SIVenv chimeric virus both of them
expressing the cherry protein. The cells were harvested 48 h post-infection and cell-associated virus titers were determined using the TCID50 method. All growth curves were
performed in triplicate. (B) Propagation rate of MV/SIVenv chimeric virus compared to SIV. One million cells were infected in 6-well plates at a MOI=0.1 with MV/SIVenv chimeric
virus (open diamonds) or SIVmac251 (black squares). The percentage of infected cells was determined at each time point by ﬂow cytometry using either the Cherry protein
ﬂuorescence or an intracellular SIVgag staining. (C) Growth kinetics of MV/SIVenv chimeric virus in CEMX174 T-cells. 400,000 cells were infected in a 12-well plate at a MOI=0.1
with MV/SIVenv chimeric virus. Cells were collected at 16 h, 24 h, 38 h, 47 h, 71 h, and 96 h post-infection. TCID50 was determined in CEMX174 cells by the Spearman and Kärber
method. (D) Characteristic growth kinetics of MVSchw virus in Vero cells.
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the anchoring of SIV gp160 to their surface. Gold particles were also
observed on the surface of budding viruses. In contrast, no gold
particles were observed on the surface of MVSchw particles in control
cells. We have previously observed that HIV gp160 expressed from
recombinant MV, as an additional gene, is not incorporated on MV
particles (Guerbois et al., 2009). The present observation validates our
choice to anchor SIVgp160 with the intracytoplasmic tail of MV-F
protein, as supported by previous studies (Foley et al., 2002; Rouxel et
al., 2009; Spielhofer et al., 1998).Fig. 4. Expression of MV-N and SIV gp160 in MV/SIVenv infected cells. Expression of
MV-Nucleoprotein (A) and SIV gp160 (B) was detected by Western blotting using cell
lysates from CEMx174 cells infected by MV-SIVenv chimeric virus at MOI=0.1 and
harvested 48 h post-infection. Cell lysates from Vero cells infected by MVSchw and
from CEMx174 cells infected by SIVMac239 were used as positive controls. Both gp160
and gp120 are detected indicating a correct cleavage of the gp160.The MV–SIVenv chimeric virus acquired HIV/SIV tropism
The aim of constructing a chimeric replicating MV expressing
native SIV gp160 spikes on its surface was to obtain a virus targeting
CD4+/CCR5+ cells, in the same way as HIV/SIV. Used as an HIV
candidate vaccine, this virus would exhibit both HIV tropism and
replicate in dendritic cells, macrophages and lymphocytes, thus
mimicking transient HIV-like infection. To analyze the effect of the
exchange of surface glycoproteins on viral tropism, we cultured the
MV/SIVenv virus in different cell lines supporting the replication of
HIV/SIV or MV. Attenuated MV vaccine strains are known to replicate
inefﬁciently in CD4 T cells, which are the main targets of HIV and SIV.
We thus compared the capacity of the MV/SIVenv chimeric virus to
infect CD4+ cells, and ﬁbroblastic cell lines that do not express CD4
receptors. Cells were infected at an MOI of 0.1, and infection was
detected by the presence of CPE and red ﬂuorescence. The MV/SIVenv
chimeric virus replicated in all the CD4+/CCR5+ cells tested, namely
CEMx174, MT4, HeLa P4C5, primary CD4+ human lymphocytes, and
primary macaque splenocytes (Table 1). Jurkat cells, which express
only CXCR4 co-receptor, were poorly infected, conﬁrming the tropism
of SIVmac239 for CCR5. In contrast, CD4-negative cell lines such as
Vero, MRC5, HeLa and U937 were unable to support MV/SIVenv
infection. To conﬁrm that the chimeric virus has lost its original CD46
tropism, we infected HeLa and Vero cells, which are typical CD46+
target cells for MV vaccine strains, with the parental MVSchw
(Cherry) andMV/SIVenv (Cherry). We observed typical large syncytia
with red ﬂuorescence in HeLa and Vero cells infected by MVSchw,
Fig. 5. Expression of SIV gp160 glycoprotein on the surface andMV-Nucleoprotein in the cytoplasm of cells infected with MV/SIVenv chimeric virus. Hela P4C5 cells were infected by
MV/SIVenv virus at MOI=0.1 then ﬁxed 24 h post-infection with PFA 4%. (A) Cell nuclei are shown in Dapi coloration. (B) The expression of MV nucleoprotein N was detected by
immunoﬂuorescence using a FITC-labeled mouse anti-MV-Nmonoclonal antibody; the expression of SIV gp160 was detected using a mouse anti-SIV gp41 monoclonal antibody and
a FITC anti-mouse IgG as secondary antibody. (C) The expression of the cherry protein is in red. (D) Merge.
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with MV/SIVenv chimeric virus (Fig. 7). In contrast, HeLa P4C5 cells
were infected with the chimera (Fig. 7). Overall, these results
demonstrate that this chimeric MV has acquired the capacity to infect
CD4+/CCR5+ cells, as SIV/HIV, and has lost his original tropism for
non-CD4+ ﬁbroblastic cells.
Discussion
We describe in this report the design, production and character-
ization of a replicating MV/SIV chimeric virus constructed by
replacing the MV H and F surface glycoproteins with the SIV gp160
envelope glycoprotein. This chimeric virus was generated from a
previously cloned live-attenuated Schwarz vaccine strain of measlesFig. 6. Electron microscopy observation of MV/SIVenv chimeric virus. HeLa P4C5 cells were in
for 22 h. Cells were ﬁxed and analyzed by transmission electron microscopy at 80 kV. Shown
×20000) and isolated particles (C, D magniﬁcation, ×80000). (E) Electron microscopy obse
gp160 immunostaining with 10-nanometer colloidal gold particles was performed, showinvirus (Combredet et al., 2003). The SIV gp160 sequence was cloned
downstream of the MV-F gene promoter and was followed by the MV
H/L intergenic region, such that it is expressed as an MV transcript.
The transmembrane domain of SIV gp41 was preserved in order to
promote trimeric gp160 assembly, and the gp41 intracytoplasmic
domain was replaced by the MV-F intracytoplasmic sequence in order
to favor anchoring of the chimeric gp160 on MV particles. The
presence of an additional transcription unit within the chimeric virus
genome allows the expression of additional genes. We readily rescued
the chimeric virus by coculturing transfected helper cells with CD4+
target cells. In infected CEMx174 cells, a cytopathic effect is reﬂected
by the presence of large cell aggregates evolving to form syncytia, as
observed during SIV infection. High viral titers were obtained after 2–
3 days of culture. The chimeric virus replicated at the same rate thanfected at anMOI of 0.1 with MV-SIVenv chimera (A, C, E) or MV-Schw (B, D) as a control
are typical viral particles observed trapped between infected cells (A, B magniﬁcation
rvation of MV-SIVenv chimeric virus after immunogold labeling of SIV gp160. Anti-SIV
g the presence of gold particles on the surface of viral particles. Bars indicate the scale.
Table 1
Tropism of MV/SIVenv chimeric virus.
Cells Organism CD4 Infectivitya
CEMx174 Homo sapiens + +++
HeLa P4C5 Homo sapiens + +++
MT4 Homo sapiens + ++
Jurkat Homo sapiens + +
CD4+ Lymphocytes Homo sapiens + +++
Splenocytes Maccaca cynomolgus + +
HeLa Homo sapiens − −
MRC5 Homo sapiens − −
Vero Cercopithecus aethiops (AGM) − −
U937 Homo sapiens − −
a Symbols: (−) no infection; (+) b10% infection; (++) 25–75% infection; (+++)
N75% infection.
122 T. Mourez et al. / Virology 419 (2011) 117–125MV, which is much faster than SIV. This capacity might be an
advantage for its immunogenic properties in vivo. The morphology of
the chimeric virus was identical to that of the parent MV particles,
indicating that MV particle morphology is not shaped by envelope
proteins but rather by the matrix M protein (Spielhofer et al., 1998).
We detected SIV gp160 expression by the chimeric virus in cell lysates
and on the surface of infected cells. The presence of gp160 anchored
on the surface of viral particles was observed by immunoelectron
microscopy. As expected from previous studies (Foley et al., 2002;Fig. 7. MV/SIVenv chimeric virus has lost CD46 tropism and acquired CD4/CCR5
tropism. HeLa and Vero cells, which are CD46+ target cells of MV vaccine strains, are
infected with standard MV-cherry, but not with MV/SIVenv-cherry (A, B, C, D, E and F).
In contrast, HeLa P4C5, which are knock-in HeLa cells expressing CD4/CCR5 receptors,
are infectedbyMV/SIVenv-cherry, showing a cythopatic effect and redﬂuorescence (G,H).Rouxel et al., 2009; Spielhofer et al., 1998), successful incorporation of
a foreign envelope protein on the surface of measles virus, as on rabies
virus, depends strictly on the presence of the original intracytoplasmic
domain interacting efﬁciently with the matrix M protein. When
expressed with its own gp41 intracytoplasmic domain, HIV-1 gp160
was not incorporated on MV particles (Guerbois et al., 2009). Speciﬁc
sequences of HIV/SIV Env cytoplasmic tail have been shown to be
responsible for slowing and reducing its cell and viral surface
expression (Abrahamyan et al., 2005; Bultmann et al., 2001).
Replacing the cytoplasmic tail by that of MV-F protein likely abolished
this property. Therefore, Env incorporation into virions might be
enhanced. However, enumerating the number of Env trimers on the
surface of virions is difﬁcult and requires the use of complex
techniques such as cryo-electron microscopy and speciﬁc antibodies
of very high afﬁnity that are poorly available for SIV. The antibodies
that we used in this work did not allow enumerating accurately the
number of Env trimers on the surface of chimeric virus. However,
whatever the number of biologically active Env trimers on its surface,
the infectivity of the chimeric virus was improved as compared to SIV
because its replicative rate was accelerated as shown in Fig. 3C.
The presence of SIV gp160 as the only envelope protein on the
surface of MV/SIVenv chimeric particles altered the cell tropism of the
new virus from CD46+ epithelial cells to CD4+/CCR5+ cells (both
cell lines and primary human and macaque cells). In contrast, CD4-
negative cell lines such as Vero, MRC5 and U937, currently used to
replicate MV, did not support MV/SIVenv infection, conﬁrming that
the chimeric virus had lost its original CD46 tropism. MV/SIVenv
chimeric particles incorporate gp160 on their surface, and their
budding progeny exhibit efﬁcient fusion on CD4+/CCR5+ cells,
indirectly demonstrating the functional trimeric conﬁguration of
gp160 that is required to elicit neutralizing antibodies (Mascola and
Monteﬁori, 2010). This efﬁcient fusion capacity of chimeric gp160 is
due to the capacity of the SIV gp41 transmembrane domain and the
MV-F intracytoplasmic domain to assemble the envelope protein in
trimeric form.
Used as an HIV candidate vaccine, the MV/SIVenv chimeric virus
would mimic transient HIV-like infection, beneﬁting both from HIV-
like tropism and the capacity of MV to replicate in dendritic cells,
macrophages and lymphocytes. This might be expected to confer a
level of protection similar to that provided by immunizationwith live-
attenuated SIV, an approach that cannot be transposed to humans.
HIV-1 mainly enters the body through mucosal sites during sexual
intercourse. Thus, the presence of neutralizing antibodies and efﬁcient
cell-mediated immunity at these sites is crucial for preventing viral
entry and early steps of dissemination (Monteﬁori and Mascola,
2009). Indeed, so-called elite HIV-1 controllers, who have persistently
low viral load in the absence of therapy, have signiﬁcantly stronger
and more complex mucosal immune responses than antiretroviral-
treated patients (Ferre et al., 2009). It was recently reported that
mucosal antibodies induced by efﬁcient immunization fully protect
primates from vaginal challenge (Bomsel et al., 2011).
In the Call for replicating vector prime-protein boost strategies in HIV
vaccine design (Malkevitch and Robert-Guroff, 2004), it was elegantly
demonstrated that replicating vectors expressing an optimally
designed envelope have numerous advantages for the induction of
protective mucosal immunity. The capacity of live-attenuated MV
vaccines to induce strong and durable protective immunity mediated
by CD4/CD8 T cells and persistent neutralizing antibodies to the viral
envelope is probably related to a very speciﬁc gene signature, as
demonstrated for the yellow fever vaccine YF-17D (Pulendran, 2009;
Querec et al., 2009). Because such signatures result from the stress
induced by the replicating vaccine virus, our MV/SIVenv chimera
might beneﬁt, as a candidate vaccine, from the capacity of MV to
induce very potent mucosal protection mediated by neutralizing
antibodies to surface glycoproteins. Administered to subjects with
pre-existing immunity to MV, this chimeric virus would escape MV-
123T. Mourez et al. / Virology 419 (2011) 117–125neutralizing antibodies. It could also be used as a booster following
administration of a recombinant MV. Live, non-persistent chimeric
viruses based on the safest human live attenuated vaccine have not
previously been evaluated as HIV candidate vaccines, although similar
chimeric viruses are already developed for immunization against
dengue and other arboviruses. Based on intertypic envelope exchange
within the yellow-fever 17D vaccine backbone, this Chimerivax®
technology shows promising clinical results (Guirakhoo et al., 2004;
Guy et al., 2010).
There are currently no suitable mousemodels in which to evaluate
the immunogenicity and preventive efﬁcacy of the MV/SIVenv
candidate vaccine. Genetically modiﬁed CD46-IFNAR mice that
express CD46 (the human receptor for MV vaccine strains) and lack
the INF-α/β receptor are susceptible to MV infection (Mrkic et al.,
1998, 1999) and have been used as a model to evaluate the
immunogenicity of MV recombinants (Combredet et al., 2003;
Desprès et al., 2005; Guerbois et al., 2009; Lorin et al., 2004, 2005b;
Singh et al., 1999). However, these mice could not sustain the
replication of ourMV/SIVenv chimeric virus, which has lost its original
tropism.Mice expressing SLAM, the human receptor for wild-typeMV
strains (Sellin et al., 2006; Welstead et al., 2005), are also unsuitable.
We will therefore evaluate the protective capacity of MV/SIVenv in
the macaque model. With its Cherry protein marker, this virus will
enable the cell types supporting gp160-dependent infection to be
identiﬁed in vivo after intravenous or mucosal administration. The
humoral and cell-mediated immunity elicited will be evaluated, and
the capacity of different vaccination schedules to protect from
autologous SIVMAC251 challenge will be assessed.
Materials and methods
Cells and tropism assay
Stable HEK-293-T7-NP human embryonic kidney cells generated
by transduction with recombinant lentiviral vectors and cloning
(Tangy et al., 2006) were used for viral rescue. They were maintained
in Dulbecco's minimal essential medium (DMEM) supplemented with
10% fetal calf serum. CEMx174 hybrid lymphoblastic cells were
maintained in RPMI medium supplemented with 10% fetal calf serum
(Salter et al., 1985). P4C5 cells (HeLa, CD4+, CXCR4+, CCR5+,
HIVLTR–LacZ+) (Marechal et al., 1998) were cultured in DMEM 10%
FCS supplemented with 0.5 mg/ml G418 (Geniticin; Gibco). For
tropism assays, primary human CD4+ T lymphocytes, primary
Maccaca cynomolgus splenocytes, and the MT4, Jurkat, and U937
human cell lines were cultured in RPMI supplemented with 10% fetal
calf serum.MRC5 and Vero cells weremaintained in DMEM-Glutamax
(Gibco-BRL) supplemented with 10% fetal calf serum.
Plasmid construction
The chimeric plasmid was constructed from the pTM-MVSchw-
eGFP plasmid (Fig. 1A), which contains an infectious MV cDNA
corresponding to the antigenome of the Schwarz MV vaccine
strain and expresses the eGFP protein in an additional transcrip-
tion unit (Combredet et al., 2003). The eGFP sequence was
replaced by the sequence coding for RFP-STREPtag protein (Cherry
red ﬂuorescent protein) between the BsiW1 and BssHII sites. This
tag protein was chosen because it is smaller and more sensitive
than eGFP. To replace the MV envelope glycoprotein genes by
those of SIV, the fragment between the two SpeI sites ﬂanking the
F and H genes in pTM-MVSchw-eGFP was removed and subcloned
into a pBS vector, designated pBS-Schw-Spe5803. A chimeric cDNA
was then synthesized (Genecust), containing successively, from
NarI to SpeI: (i) the MV M/F intergenic region, (ii) the SIVmac239
gp160 sequence, in which the intracytoplasmic domain was
replaced by that of MV-F, and (iii) the MV H/L intergenic region(Fig. 1C). The SIVgp160 sequence was optimized to Macacca codon
usage and modiﬁed to remove a SpeI restriction site and to avoid
the following cis-active elements: internal TATA-boxes, chi-sites,
ribosomal entry sites, AT- or GC-rich sequences, ARE, INS and CRS
sequence elements, repeated sequences, RNA secondary struc-
tures, cryptic splice donor and acceptor sites, and branch points.
This optimization also avoided MV editing-like sequences. The
whole construct respected the ‘rule of 6’ of the MV genome (Calain
and Roux, 1993). A BamHI site was added to the 3′ end of the
synthetic sequence to enable introduction of the cassette into the
pBS-Schw-Spe5803 plasmid. To replace the MV H and F sequences
by the modiﬁed SIVenv gene, the chimeric synthetic sequence was
recombined into the pBS-Schw-Spe5803 plasmid after NarI/BamHI
digestion. This plasmid was designated pBS-Schw-chim/siv/env.
The new modiﬁed sequence was then introduced into the pTM-
MVSchw-RFP-STREPtag vector after SpeI digestion. The resulting
vector was designated pTM-MVSchw-Chim-SIVenv (Cherry).
Rescue of the MV/SIV chimera
The chimeric MV/SIV virus was rescued from the pTM-MVSchw-
Chim-SIVenv (Cherry) plasmid as previously described (Combredet et
al., 2003), by using a helper-cell-based rescue system (Radecke et al.,
1995) (Parks et al., 1999), modiﬁed to recover the virus in CD4 cells.
Brieﬂy, HEK-293-T7-MV human embryonic kidney helper cells
(Guerbois et al., 2009; Tangy et al., 2006) were transfected with the
pTM-MVSchw-Chim-SIVenv (Cherry) plasmid and then co-cultured
with CEMx174 cells for 3 days. Positive rescue was shown by a
cytopathic effect (CPE) and red ﬂuorescence generated by the Cherry
protein. CPE and red ﬂuorescence generally appeared after 3–5 days of
co-culture. To amplify the virus, fresh CEMx174 cells were added
twice a week and culture was continued until almost all the cells were
infected. To harvest the virus, cells were centrifuged and freeze-
thawed. After clariﬁcation, cell lysates were titrated and used as an
inoculum for subsequent virus production.
Virus titration and growth kinetics
Titers of the chimeric virus were determined by using an
endpoint dilution assay on CEMx174 cells. Brieﬂy, CEMx174 cells
were infected for 2 h under low-speed centrifugation (1000 rpm)
in sterile Eppendorff tubes with serial 1:10 dilutions of virus
suspension in RPMI supplemented with 10% FCS. Infected cells
were seeded in 96-well plates (25000 cells in 100 μL of RPMI/well)
and incubated for 24 h at 37 °C. After 24 h, 100 μL of RPMI-10% FCS
was added to each well and the cells were incubated for 4 days.
The cells were observed daily for CPE and red ﬂuorescence. Fifty-
percent tissue culture infective doses (TCID50) were calculated
with the Spearman and Kärber method. To determine the
replicative capacity of the chimeric virus, CEMx174 cells were
infected with viral suspension for 2 h at a multiplicity of infection
(MOI) of 0.1, under low-speed centrifugation (1000 rpm). Infected
CEMx174 cells were seeded in 12-well plates at 400000 cells/well.
At various times post-infection, cells were harvested and centri-
fuged at 1000 rpm. After a round of freeze thawing and removal of
cell debris by low-speed centrifugation, virus titers were deter-
mined by limiting dilution assay on CEMx174 cells as described
above. To compare the growth capacity of SIV to the chimeric
virus, six-well plates were seeded with 106 CEMx174 cells and
infected at a MOI 0.1 by either MV/SIVenv virus or SIVmac251. At
different time points, the percentage of infected cells was
determined by FACS analysis. Cells were washed twice with PBS
and 2% FCS, and then ﬁxed in PBS containing 4% paraformaldehyde
(v/v). Cells infected by the MV/SIVenv chimeric virus were
detected with the Cherry protein ﬂuorescence. Cells infected
with SIV were ﬁxed then permeabilized with PermWash buffer
124 T. Mourez et al. / Virology 419 (2011) 117–125(BD Bioscience), incubated with an anti SIVgag KK64 mouse
antibody (obtained through the NIBSC Centralized Facility for AIDS
Reagents) at 4 °C for 20 min, then with an Alexa Fluor® 488 goat
anti-mouse IgG (H+L) as secondary antibody. After washing in
PBS ﬂow cytometry analysis was performed using a FACScalibur
(Becton Dickinson).Immunoﬂuorescence detection
To detect the expression of MV-N and SIV-env proteins, immuno-
ﬂuorescence staining was performed on infected HeLa P4C5 cells ﬁxed
with 4% PFA solution (v/v). Surface SIV-env immunostaining was
performed after incubating the cells for 1 h in blocking solution (PBS 2%
goat serum), with a 1/300-diluted mouse anti-SIVMac251gp160/gp120
monoclonal antibody (KK17; obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH, fromDrKaren
Kent and Ms Caroline Powell; courtesy of the NIBSC Centralized Facility
for AIDS Reagents). Intracytoplasmic immunostaining was performed
after incubating the cells for 1 h in blocking/permeabilizing solution
(PBS, 2% goat serum, 0.1% saponin), with a mouse anti-MV-N mAb
(MAB8906F; Chemicon International). In both cases the secondary
antibodywas a FITC-conjugated sheepanti-mouse IgG antibody (74641,
BioRad).After2washing steps inPBS, cell nucleiwere stainedwithDAPI.Western blotting
CEMx174 cells were infectedwith theMV-SIVenv chimeric virus at an
MOIof0.1. Infectedcellswere collected48 h laterand lysedwithcomplete
EDTA-free protease inhibitor (Roche) in 120 mM NaCl solution. Protein
lysates were separated (50 ng per well) by SDS-PAGE electrophoresis on
4–12% NUPAGE® Bis-Tris gels with MOPS running buffer (Invitrogen)
before transfer to cellulose membranes with the XCell SureLock™ system
(Invitrogen). To detect the SIVgp160 andMV-N proteins, themembranes
wereblottedwith amouse anti-SIVgp160/gp120V2monoclonal antibody
(KK13; obtained from the Programme EVA Centre for AIDS Reagents,
NIBSC, UK, supported by the EC FP6/7 Europrise Network of Excellence,
AVIP and NGIN consortia and the Bill and Melinda Gates GHRC-CAVD
Project and donated by Dr Karen Kent, NIBSC Centralized Facility for AIDS
Reagents), or a mouse anti-MV N mAb (MAB8906F; Chemicon Interna-
tional). A sheep anti-mouse IgG-horseradish peroxidase (HRP) conjugate
(NA931V; GE Healthcare) was used as secondary antibody. Peroxidase
activity was visualized with an enhanced chemiluminescence detection
kit (Pierce).Electron microscopy
HeLa P4C5 cells were seeded on glass coverslips and infected at an
MOI of 0.1 with the MV–SIVenv chimera. The cells were ﬁxed 22 h
later with 2% PFA in PBS for 5 min and with 4% PFA for 2 h at room
temperature. Non-speciﬁc sites were saturated for 10 min with 1%
bovine serum albumin, and the cells were probed for 40 min with the
mouse anti-SIVMac251gp160/gp120 monoclonal antibody KK17
(NIH-AIDS Research and Reference Reagent Program) in PBS–1%
BSA. After washing, the cells were incubated for 20 min with 10-nm
colloidal gold particles coated with protein A (University Medical
Center, Utrecht). The cells were then ﬁxed in 2.5% glutaraldehyde in
0.1 M sodium cacodylate buffer overnight at 4 °C, postﬁxed with 1%
osmic acid, dehydrated in ethanol, and embedded in Epon. Ultrathin
sections (70–80 nm) were cut with a diamond knife, stained with
uranyl acetate and Reynolds lead citrate, and observed at 80 kV
accelerating voltage in a JEOL JEM 1010 electronmicroscope equipped
with an Eloïse Mega View III camera. Non-infected cells and HeLa
P4C5 cells infected with MV-Schw were used as controls.Acknowledgments
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